Literature DB >> 23241187

Current drug discovery strategies against arenavirus infections.

Antonella Pasquato1, Dominique J Burri, Stefan Kunz.   

Abstract

Arenaviruses are a large group of emerging viruses including several causative agents of severe hemorrhagic fevers with high mortality in man. Considering the number of people affected and the currently limited therapeutic options, novel efficacious therapeutics against arenaviruses are urgently needed. Over the past decade, significant advances in knowledge about the basic virology of arenaviruses have been accompanied by the development of novel therapeutics targeting different steps of the arenaviral life cycle. High-throughput, small-molecule screens identified potent and broadly active inhibitors of arenavirus entry that were instrumental for the dissection of unique features of arenavirus fusion. Novel inhibitors of arenavirus replication have been successfully tested in animal models and hold promise for application in humans. Late in the arenavirus life cycle, the proteolytic processing of the arenavirus envelope glycoprotein precursor and cellular factors critically involved virion assembly and budding provide further promising 'druggable' targets for novel therapeutics to combat human arenavirus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241187     DOI: 10.1586/eri.12.117

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  2 in total

1.  Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor.

Authors:  Yi-Ying Chou; Christian Cuevas; Margot Carocci; Sarah H Stubbs; Minghe Ma; David K Cureton; Luke Chao; Frances Evesson; Kangmin He; Priscilla L Yang; Sean P Whelan; Susan R Ross; Tom Kirchhausen; Raphaël Gaudin
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.

Authors:  Ziying Han; Jianhong Lu; Yuliang Liu; Benjamin Davis; Michael S Lee; Mark A Olson; Gordon Ruthel; Bruce D Freedman; Matthias J Schnell; Jay E Wrobel; Allen B Reitz; Ronald N Harty
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.